As an internist and lipidologist, I’ve spent decades parsing data on statins, ezetimibe, PCSK9 inhibitors, and the endless parade of “LDL-lowering breakthroughs.” Yet the most potent, and perhaps the most underappreciated, intervention to prevent heart attacks each winter doesn’t come from a cardiology journal or a pharmaceutical rep. It comes from your local pharmacy fridge. For years, I’ve told my patients that getting a flu shot may prevent a heart attack more effectively than starting a statin. That’s not hyperbole; it’s data.

A landmark self-controlled case series in The New England Journal of Medicine found that the risk of myocardial infarction (MI) jumped sixfold in the seven days after lab-confirmed influenza infection. Catching the flu, it turns out, is like lighting a short fuse on a ticking cardiovascular bomb. Then came the IAMI trial, which randomized hospitalized post-MI patients to receive a flu vaccine or placebo before discharge. Results that would make any cardiologist jealous:

All-cause mortality: 4.9 percent -> 2.9 percent (ARR 2.0 percent, NNT ~50)
Cardiovascular death: 4.5 percent -> 2.7 percent (ARR 1.8 percent, NNT ~56)
Composite (death + MI + stent thrombosis): 7.2 percent -> 5.3 percent (ARR 1.9 percent, NNT ~53)

Those absolute risk reductions rival, and in some subgroups exceed, what we expect from statins. And the protection began within weeks (not years) and without myalgias, liver panels, or prior authorizations.

Influenza infection drives cytokine release, endothelial dysfunction, platelet activation, and the pro-thrombotic environment that turns a stable plaque into a ruptured one. Preventing the infection prevents the spark. It’s not lowering cholesterol; it’s lowering ignition potential. Maybe because there’s no patent, no rebate card, no glossy booth at ACC. Maybe because “get your flu shot” sounds too simple for grand rounds. Maybe because prevention that lives in the public-health domain never gets the marketing push of a molecule that lives in a pipeline. But if we judge by absolute risk reduction, not brand visibility, the $25 vaccine outperforms plenty of branded drugs that dominate our guidelines and formularies.

Here’s what I tell my patients: “Your statin lowers long-term risk. Your flu shot lowers next week’s risk.” That framing clicks. It turns prevention into something immediate and concrete, especially for patients who struggle to see the payoff of abstract lab numbers. A meta-analysis in JACC found influenza vaccination reduced major adverse cardiovascular events (MACE) by 36 percent overall and 55 percent in patients with recent ACS. Few interventions in cardiology deliver that kind of effect for that kind of cost. If we ranked interventions by absolute risk reduction rather than brand visibility, the humble flu shot would be at the top of every cardiology guideline. Until then, I’ll keep recommending it as what it is: a free, evidence-based, anti-inflammatory, anti-thrombotic, short-term statin that lives in your local CVS.

Larry Kaskel is an internist and “lipidologist in recovery” who has been practicing medicine for more than thirty-five years. He operates a concierge practice in the Chicago area and serves on the teaching faculty at the Northwestern University Feinberg School of Medicine. In addition, he is affiliated with Northwestern Lake Forest Hospital.

Before podcasts entered mainstream culture, Dr. Kaskel hosted Lipid Luminations on ReachMD, where he produced a library of more than four hundred programs featuring leading voices in cardiology, lipidology, and preventive medicine.

He is the author of Dr. Kaskel’s Living in Wellness, Volume One: Let Food Be Thy Medicine, works that combine evidence-based medical practice with accessible strategies for improving healthspan. His current projects focus on reevaluating the cholesterol hypothesis and investigating the infectious origins of atherosclerosis. More information is available at larrykaskel.com.